|
1
|
Wu F, Li J, Jang C, Wang J and Xiong J:
The role of Axl in drug resistance and epithelial-to-mesenchymal
transition of non-small cell lung carcinoma. Int J Clin Exp Pathol.
7:6653–6661. 2014.PubMed/NCBI
|
|
2
|
Kocher F, Pircher A, Mohn-Staudner A,
Romeder F, Duller W, Steinmaurer M, Eckmayr J, Schmid T, Hilbe W,
Fiegl M and Greil R: Multicenter phase II study evaluating
docetaxel and cisplatin as neoadjuvant induction regimen prior to
surgery or radiochemotherapy with docetaxel, followed by adjuvant
docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA
and IIIB (TAX-AT 1.203 Trial). Lung Cancer. 85:395–400. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Juhász E, Kim JH, Klingelschmitt G and
Walzer S: Effects of erlotinib first-line maintenance therapy
versus placebo on the health-related quality of life of patients
with metastatic non-small-cell lung cancer. Eur J Cancer.
49:1205–1215. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pircher A, Manzl C, Fiegl M, Popper H,
Pirker R and Hilbe W: Overcoming resistance to first generation
EGFR TKIs with cetuximab in combination with chemotherapy in an
EGFR mutated advanced stage NSCLC patient. Lung Cancer. 83:408–410.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rolfo C, Giovannetti E, Hong DS, Bivona T,
Raez LE, Bronte G, Buffoni L, Reguart N, Santos ES, Germonpre P, et
al: Novel therapeutic strategies for patients with NSCLC that do
not respond to treatment with EGFR inhibitors. Cancer Treat Rev.
40:990–1004. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hanna N, Shepherd FA, Fossella FV, Pereira
JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M,
Muller T, et al: Randomized phase III trial of pemetrexed versus
docetaxel in patients with non-small-cell lung cancer previously
treated with chemotherapy. J Clin Oncol. 22:1589–1597. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu C, Wang Y, Xia Y, He S, Wang Z, Chen Y,
Wu C, Shu Y and Jiang J: Wilms' tumor 1 enhances
Cisplatin-resistance of advanced NSCLC. FEBS Lett. 588:4566–4572.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Daniels MG, Bowman RV, Yang IA, Govindan R
and Fong KM: An emerging place for lung cancer genomics in 2013. J
Thorac Dis. 5 (Suppl 5):S491–S497. 2013.PubMed/NCBI
|
|
9
|
Ke Y, Zhao W, Xiong J and Cao R:
Downregulation of miR-16 promotes growth and motility by targeting
HDGF in non-small cell lung cancer cells. FEBS Lett. 587:3153–3157.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xin C, Zhang H and Liu Z: miR-154
suppresses colorectal cancer cell growth and motility by targeting
TLR2. Mol Cell Biochem. 387:271–277. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cheng Z, Ma R, Tan W and Zhang L: MiR-152
suppresses the proliferation and invasion of NSCLC cells by
inhibiting FGF2. Exp Mol Med. 46:e1122014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Su Y, Wang Y, Zhou H, Lei L and Xu L:
MicroRNA-152 targets ADAM17 to suppress NSCLC progression. FEBS
Lett. 588:1983–1988. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Amable L: Cisplatin resistance and
opportunities for precision medicine. Pharmacol Res. 106:27–36.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fennell DA, Summers Y, Cadranel J, Benepal
T, Christoph DC, Lal R, Das M, Maxwell F, Visseren-Grul C and Ferry
D: Cisplatin in the modern era: The backbone of first-line
chemotherapy for non-small cell lung cancer. Cancer Treat Rev.
44:42–50. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim ES: Chemotherapy resistance in lung
cancerLung Cancer and Personalized Medicine. Springer International
Publishing; pp. 189–209. 2016, View Article : Google Scholar
|
|
17
|
Li S, Lei Y, Jia Y, Li N, Wink M and Ma Y:
Piperine, a piperidine alkaloid from Piper nigrum re-sensitizes
P-gp, MRP1 and BCRP dependent multidrug resistant cancer cells.
Phytomedicine. 19:83–87. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang W, Liu G and Zheng J: Human renal
UOK130 tumor cells: A drug resistant cell line with highly
selective over-expression of glutathione S-transferase-pi isozyme.
Eur J Pharmacol. 568:61–67. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mansoori B, Mohammadi A, Davudian S,
Shirjang S and Baradaran B: The different mechanisms of cancer drug
resistance: A brief review. Adv Pharm Bull. 7:339–348. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rodriguez-Barrueco R, Nekritz EA, Bertucci
F, Yu J, Sanchez-Garcia F, Zeleke TZ, Gorbatenko A, Birnbaum D,
Ezhkova E, Cordon-Cardo C, et al: miR-424(322)/503 is a breast
cancer tumor suppressor whose loss promotes resistance to
chemotherapy. Genes Dev. 31:553–566. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Heavey S, Barr M, Edwards C, O'Byrne K and
Gately K: 7 NFkB-IκBα interaction: A mechanism of resistance to
cisplatin in NSCLC. Lung Cancer. 75 (Suppl 1):S32012. View Article : Google Scholar
|
|
22
|
Li Y, Liang Y, Sang Y, Song X, Zhang H,
Liu Y, Jiang L and Yang Q: MiR-770 suppresses the chemo-resistance
and metastasis of triple negative breast cancer via direct
targeting of STMN1. Cell Death Dis. 9:142018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang Y, Bao W, Liu Y, Wang S, Xu S, Li X,
Li Y and Wu S: miR-98-5p contributes to cisplatin resistance in
epithelial ovarian cancer by suppressing miR-152 biogenesis via
targeting Dicer1. Cell Death Dis. 9:4472018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tan W, Liao Y, Qiu Y, Liu H, Tan D, Wu T,
Tang M, Zhang S and Wang H: miRNA 146a promotes chemotherapy
resistance in lung cancer cells by targeting DNA damage inducible
transcript 3 (CHOP). Cancer Lett. 428:55–68. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang JS, Li BJ, Lu HW, Chen Y, Lu C, Zhu
RX, Liu SH, Yi QT, Li J and Song CH: Serum miR-152, miR-148a,
miR-148b, and miR-21 as novel biomarkers in non-small cell lung
cancer screening. Tumour Biol. 36:3035–3042. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dou H, Wang Y, Su G and Zhao S: Decreased
plasma let-7c and miR-152 as noninvasive biomarker for
non-small-cell lung cancer. Int J Clin Exp Med. 8:9291–9298.
2015.PubMed/NCBI
|
|
27
|
Zeng K, Chen X, Xu M, Liu X, Hu X, Xu T,
Sun H, Pan Y, He B and Wang S: CircHIPK3 promotes colorectal cancer
growth and metastasis by sponging miR-7. Cell Death Dis. 9:4172018.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rottiers V, Najafi-Shoushtari SH, Kristo
F, Gurumurthy S, Zhong L, Li Y, Cohen DE, Gerszten RE, Bardeesy N,
Mostoslavsky R and Näär AM: MicroRNAs in metabolism and metabolic
diseases. Cold Spring Harb Symp Quant Biol. 76:2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen J, Tian W, Cai H, He H and Deng Y:
Down-regulation of microRNA-200c is associated with drug resistance
in human breast cancer. Med Oncol. 29:2527–2534. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xu K, Liang X, Cui D, Wu Y, Shi W and Liu
J: miR-1915 inhibits Bcl-2 to modulate multidrug resistance by
increasing drug-sensitivity in human colorectal carcinoma cells.
Mol Carcinog. 52:70–78. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fu X, Tian J, Zhang L, Chen Y and Hao Q:
Involvement of micro RNA-93, a new regulator of PTEN/Akt signaling
pathway, in regulation of chemotherapeutic drug cisplatin
chemosensitivity in ovarian cancer cells. FEBS Lett. 586:1279–1286.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang C, Wang S, Ma F and Zhang W:
miRNA-328 overexpression confers cisplatin resistance in non-small
cell lung cancer via targeting of PTEN. Mol Med Rep. 18:4563–4570.
2018.PubMed/NCBI
|
|
33
|
Chen L, Wang Y, He J, Zhang C, Chen J and
Shi D: Long noncoding RNA H19 promotes proliferation and invasion
in human glioma cells by downregulating miR-152. Oncol Res. 2018.
View Article : Google Scholar
|
|
34
|
Chen MJ, Cheng YM, Chen CC, Chen YC and
Shen CJ: MiR-148a and miR-152 reduce tamoxifen resistance in ER+
breast cancer via downregulating ALCAM. Biochem Biophys Res Commun.
483:840–846. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Marques JHM, Mota AL, Oliveira JG, Lacerda
JZ, Stefani JP, Ferreira LC, Castro TB, Aristizábal-Pachón AF and
Zuccari DAPC: Melatonin restrains angiogenic factors in
triple-negative breast cancer by targeting miR-152-3p: In vivo and
in vitro studies. Life Sci. 208:131–138. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ma J, Yao Y, Wang P, Liu Y, Zhao L, Li Z,
Li Z and Xue Y: MiR-152 functions as a tumor suppressor in
glioblastoma stem cells by targeting Krüppel-like factor 4. Cancer
Lett. 355:85–95. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wu Y, Huang A, Li T, Su X, Ding H, Li H,
Qin X, Hou L, Zhao Q, Ge X, et al: MiR-152 reduces human umbilical
vein endothelial cell proliferation and migration by targeting
ADAM17. FEBS Lett. 588:2063–2069. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Batsi C, Markopoulou S, Kontargiris E,
Charalambous C, Thomas C, Christoforidis S, Kanavaros P,
Constantinou AI, Marcu KB and Kolettas E: Bcl-2 blocks
2-methoxyestradiol induced leukemia cell apoptosis by a
p27(Kip1)-dependent G1/S cell cycle arrest in conjunction with
NF-kappaB activation. Biochem Pharmacol. 78:33–44. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Luna-López A, González-Puertos VY,
Romero-Ontiveros J, Ventura-Gallegos JL, Zentella A, Gomez-Quiroz
LE and Königsberg M: A noncanonical NF-κB pathway through the p50
subunit regulates Bcl-2 overexpression during an
oxidative-conditioning hormesis response. Free Radic Biol Med.
63:41–50. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hall C, Troutman SM, Price DK, Figg WD and
Kang MH: Bcl-2 family of proteins as therapeutic targets in
genitourinary neoplasms. Clin Genitourin Cancer. 11:10–19. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sun C, Chan F, Briassouli P and
Linardopoulos S: Aurora kinase inhibition downregulates NF-kappaB
and sensitises tumour cells to chemotherapeutic agents. Biochem
Biophys Res Commun. 352:220–225. 2007. View Article : Google Scholar : PubMed/NCBI
|
